Samsung Biologics Co Ltd
KRX:207940

Watchlist Manager
Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd
KRX:207940
Watchlist
Price: 999 999.9999 KRW Market Closed
Market Cap: 46.3T KRW

Samsung Biologics Co Ltd
Total Current Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Samsung Biologics Co Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Samsung Biologics Co Ltd
KRX:207940
Total Current Assets
â‚©6.4T
CAGR 3-Years
0%
CAGR 5-Years
32%
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Total Current Assets
â‚©330.1B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Total Current Assets
â‚©38B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Total Current Assets
â‚©623.4B
CAGR 3-Years
42%
CAGR 5-Years
44%
CAGR 10-Years
38%
N
NanoEnTek Inc
KOSDAQ:039860
Total Current Assets
â‚©57.1B
CAGR 3-Years
12%
CAGR 5-Years
13%
CAGR 10-Years
10%
E
ENCell Co Ltd
KOSDAQ:456070
Total Current Assets
â‚©35.5B
CAGR 3-Years
20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Samsung Biologics Co Ltd
Glance View

In the bustling world of biopharmaceuticals, Samsung Biologics Co Ltd has carved a niche as a formidable player, merging cutting-edge technology with industrial scale to drive its operations. Situated in Incheon, South Korea, the company emerged as a key subsidiary of Samsung Group, bringing with it the organizational prowess and strategic vision that hallmark the conglomerate. Established with the goal of reshaping the global landscape of biopharmaceutical manufacturing, Samsung Biologics offers a suite of contract development and manufacturing organization (CDMO) services. From early-stage development to large-scale production, the company supports clients through every step of a biologic's lifecycle, ensuring seamless transition from laboratory to patient. The blend of state-of-the-art facilities and advanced process technologies enables them to meet the growing demands for complex biopharmaceuticals efficiently. Samsung Biologics' revenue machine spins around its comprehensive service spectrum, which includes drug substance and product manufacturing and laboratory testing services. The contract-based model allows global pharma companies to outsource crucial parts of their development and manufacturing processes to Samsung Biologics, thus optimizing costs and timelines. By building strategic partnerships and continuously investing in expanding its manufacturing capacity, Samsung Biologics not only captures market share but also aligns itself with the burgeoning demand for biosimilars and other next-generation therapeutics. Furthermore, operating within a highly regulated and competitive industry, the company's focus on maintaining stringent quality standards and regulatory compliance cements its reputation as a trusted partner in the pharmaceutical sector.

Intrinsic Value
981 122.805 KRW
Overvaluation 2%
Intrinsic Value
Price

See Also

What is Samsung Biologics Co Ltd's Total Current Assets?
Total Current Assets
6.4T KRW

Based on the financial report for Sep 30, 2025, Samsung Biologics Co Ltd's Total Current Assets amounts to 6.4T KRW.

What is Samsung Biologics Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
32%

Over the last year, the Total Current Assets growth was 32%.

Back to Top